Work Here?
Kymera Therapeutics
Work Here?
Develops treatments using targeted protein degradation
Kymera Therapeutics
Work Here?
Develops treatments using targeted protein degradation
About Kymera Therapeutics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2016
Overview
Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which allows for more precise therapies. The company's goal is to create next-generation medicines that meet unmet medical needs, supported by partnerships with organizations like Sanofi to enhance their research and development efforts.
Simplify's Take
What believers are saying
- Increased interest in molecular glue degraders complements Kymera's existing platform.
- AI-driven drug discovery platforms enhance Kymera's drug development process.
- Growing personalized medicine trend aligns with Kymera's targeted protein degradation focus.
What critics are saying
- Increased competition from Arvinas and Nurix Therapeutics may impact Kymera's market share.
- Reliance on public offerings for funding may indicate financial instability.
- Potential delays in drug development could impact Kymera's ability to meet milestones.
What makes Kymera Therapeutics unique
- Kymera's Pegasus Platform enables precise targeting of disease-causing proteins.
- The company focuses on targeted protein degradation for cancer and immune disorders.
- Kymera's collaboration with Sanofi enhances its credibility in the pharmaceutical industry.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1278M
Above
Industry Average
Funded Over
5 Rounds
Bessemer Venture PartnersBenefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -3%2 year growth
↑ 0%Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline.To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com
WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer.
WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock
Kymera Therapeutics aims to raise $225M: The public offering will be...
Kymera Therapeutics aims to raise $225M: The public offering will be used to fund Kymera's pipeline, and some funds could be used for small acquisitions or in-licensing deals.
Kymera Therapeutics is Hiring for 15 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Kymera Therapeutics
About Kymera Therapeutics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2016
Kymera Therapeutics is Hiring for 15 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Kymera Therapeutics